Thermage® Receives AAA Trademark Certification in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: PRnewswire
- Brand Recognition Boost: Thermage® has been awarded the AAA trademark certification by the China Trademark Association, joining an elite group of only 217 brands nationwide, which underscores its leadership in the non-invasive aesthetics market and enhances trust among consumers and practitioners.
- Increased Market Influence: This certification not only elevates Thermage®'s brand reputation but also reflects its strong market influence in China, which is expected to attract more consumers to choose the brand and drive sales growth.
- Global Treatment Experience: With over 5 million treatments performed worldwide, Thermage® demonstrates exceptional performance in the non-invasive aesthetic treatment sector, further solidifying its market leadership.
- Commitment to Innovation: Bausch Health CEO Thomas J. Appio emphasizes that this certification reflects the company's commitment to innovation and high-quality standards, which is expected to promote long-term growth in the Chinese market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHC
Wall Street analysts forecast BHC stock price to rise
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 5.360
Low
7.00
Averages
8.25
High
10.00
Current: 5.360
Low
7.00
Averages
8.25
High
10.00
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Thermage® Receives AAA Trademark Certification in China
- Brand Recognition Boost: Thermage® has been awarded the AAA trademark certification by the China Trademark Association, joining an elite group of only 217 brands nationwide, which underscores its leadership in the non-invasive aesthetics market and enhances trust among consumers and practitioners.
- Increased Market Influence: This certification not only elevates Thermage®'s brand reputation but also reflects its strong market influence in China, which is expected to attract more consumers to choose the brand and drive sales growth.
- Global Treatment Experience: With over 5 million treatments performed worldwide, Thermage® demonstrates exceptional performance in the non-invasive aesthetic treatment sector, further solidifying its market leadership.
- Commitment to Innovation: Bausch Health CEO Thomas J. Appio emphasizes that this certification reflects the company's commitment to innovation and high-quality standards, which is expected to promote long-term growth in the Chinese market.
See More
Bausch Health Announces 2026 Annual Meeting Election Results
- Board Election Results: At the 2026 Annual Meeting, all 10 director nominees were elected, including new director Eiry W. Roberts, M.D., who brings extensive experience in clinical development and medical strategy, likely providing fresh perspectives and leadership to the company.
- Voting Transparency: The voting results indicate that Eiry W. Roberts received 196,972,752 votes in favor, reflecting strong shareholder confidence in her capabilities and the company's commitment to board diversity.
- Executive Compensation Approval: Shareholders also approved, via a non-binding advisory vote, the compensation of named executive officers, indicating trust and support for the management team, which may enhance their motivation and improve company performance.
- Auditor Appointment: Shareholders approved the appointment of PricewaterhouseCoopers LLP as the company's auditor until the 2027 Annual Meeting, a decision that will ensure financial transparency and compliance, thereby boosting investor confidence.
See More
Bausch Health CEO to Participate in RBC Healthcare Conference
- Conference Participation: Bausch Health's CEO Thomas J. Appio and CFO Jean-Jacques Charhon will participate in the RBC Capital Markets 2026 Global Healthcare Conference in New York on May 20, 2026, highlighting the company's leadership in the healthcare sector.
- Live Webcast: The event will feature a live audio webcast accessible on Bausch Health's Investor Relations website, ensuring that investors and the public can receive real-time updates on the company's latest developments, thereby enhancing transparency and communication.
- Replay Availability: Following the event, a replay will be available on the Investor Relations website, further improving information accessibility and helping investors better understand the company's strategic direction.
- Company Vision: Bausch Health is committed to improving healthcare outcomes through the development and marketing of a diverse range of medical products, showcasing its integrated strength in the global healthcare market and dedication to patient care.
See More
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
- Conference Participation: Bausch Health will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference on May 19, 2026, showcasing the company's strategic direction in the healthcare sector.
- Live Webcast Details: The event is scheduled to start at 10:25 a.m. U.S. ET, allowing investors to listen live via the Investor Relations section of Bausch Health's website, enhancing interaction with stakeholders.
- Replay Availability: A replay of the event will be accessible on the investor relations website after the event, ensuring that investors who cannot attend live can still access important information, thereby increasing transparency.
- Company Background: Bausch Health is a global diversified pharmaceutical company focused on improving healthcare outcomes across various fields, including gastroenterology, neuroscience, and eye health, demonstrating its broad impact in the industry.
See More
Bausch Health Companies Reports Strong Q1 Earnings, Exceeds Estimates
- Significant Revenue Growth: Bausch Health Companies reported Q1 revenue of $2.52 billion, a 12% year-over-year increase, primarily driven by its Bausch + Lomb eyecare segment, which generated $1.24 billion, reflecting a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, surpassing analyst expectations of $0.68, indicating enhanced profitability.
- Consistent Growth Indicator: Bausch has achieved 12 consecutive quarters of year-over-year revenue growth, demonstrating stability and execution within its operations, despite its somewhat sprawling business structure.
- 2026 Financial Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, reflecting confidence in future growth.
See More
Bausch Health Beats Q1 Estimates with Strong Revenue Growth
- Significant Revenue Growth: Bausch Health reported Q1 revenue of $2.52 billion, a 12% year-over-year increase that surpassed analyst expectations of $2.42 billion, driven primarily by a strong performance in its Bausch + Lomb eyecare segment, which contributed a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, reflecting successful cost control and operational efficiency, which bolsters investor confidence in the company's financial health.
- Sustained Growth Strategy: Bausch Health has achieved 12 consecutive quarters of year-over-year revenue growth, indicating stability and execution capability despite its sprawling business structure, which may continue to attract investor interest moving forward.
- Stable Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, demonstrating management's confidence in future performance, although no profitability guidance was provided.
See More
Thermage® Receives AAA Trademark Certification in China
- Brand Recognition Boost: Thermage® has been awarded the AAA trademark certification by the China Trademark Association, joining an elite group of only 217 brands nationwide, which underscores its leadership in the non-invasive aesthetics market and enhances trust among consumers and practitioners.
- Increased Market Influence: This certification not only elevates Thermage®'s brand reputation but also reflects its strong market influence in China, which is expected to attract more consumers to choose the brand and drive sales growth.
- Global Treatment Experience: With over 5 million treatments performed worldwide, Thermage® demonstrates exceptional performance in the non-invasive aesthetic treatment sector, further solidifying its market leadership.
- Commitment to Innovation: Bausch Health CEO Thomas J. Appio emphasizes that this certification reflects the company's commitment to innovation and high-quality standards, which is expected to promote long-term growth in the Chinese market.
See More
Bausch Health Announces 2026 Annual Meeting Election Results
- Board Election Results: At the 2026 Annual Meeting, all 10 director nominees were elected, including new director Eiry W. Roberts, M.D., who brings extensive experience in clinical development and medical strategy, likely providing fresh perspectives and leadership to the company.
- Voting Transparency: The voting results indicate that Eiry W. Roberts received 196,972,752 votes in favor, reflecting strong shareholder confidence in her capabilities and the company's commitment to board diversity.
- Executive Compensation Approval: Shareholders also approved, via a non-binding advisory vote, the compensation of named executive officers, indicating trust and support for the management team, which may enhance their motivation and improve company performance.
- Auditor Appointment: Shareholders approved the appointment of PricewaterhouseCoopers LLP as the company's auditor until the 2027 Annual Meeting, a decision that will ensure financial transparency and compliance, thereby boosting investor confidence.
See More
Bausch Health CEO to Participate in RBC Healthcare Conference
- Conference Participation: Bausch Health's CEO Thomas J. Appio and CFO Jean-Jacques Charhon will participate in the RBC Capital Markets 2026 Global Healthcare Conference in New York on May 20, 2026, highlighting the company's leadership in the healthcare sector.
- Live Webcast: The event will feature a live audio webcast accessible on Bausch Health's Investor Relations website, ensuring that investors and the public can receive real-time updates on the company's latest developments, thereby enhancing transparency and communication.
- Replay Availability: Following the event, a replay will be available on the Investor Relations website, further improving information accessibility and helping investors better understand the company's strategic direction.
- Company Vision: Bausch Health is committed to improving healthcare outcomes through the development and marketing of a diverse range of medical products, showcasing its integrated strength in the global healthcare market and dedication to patient care.
See More
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
- Conference Participation: Bausch Health will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference on May 19, 2026, showcasing the company's strategic direction in the healthcare sector.
- Live Webcast Details: The event is scheduled to start at 10:25 a.m. U.S. ET, allowing investors to listen live via the Investor Relations section of Bausch Health's website, enhancing interaction with stakeholders.
- Replay Availability: A replay of the event will be accessible on the investor relations website after the event, ensuring that investors who cannot attend live can still access important information, thereby increasing transparency.
- Company Background: Bausch Health is a global diversified pharmaceutical company focused on improving healthcare outcomes across various fields, including gastroenterology, neuroscience, and eye health, demonstrating its broad impact in the industry.
See More
Bausch Health Companies Reports Strong Q1 Earnings, Exceeds Estimates
- Significant Revenue Growth: Bausch Health Companies reported Q1 revenue of $2.52 billion, a 12% year-over-year increase, primarily driven by its Bausch + Lomb eyecare segment, which generated $1.24 billion, reflecting a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, surpassing analyst expectations of $0.68, indicating enhanced profitability.
- Consistent Growth Indicator: Bausch has achieved 12 consecutive quarters of year-over-year revenue growth, demonstrating stability and execution within its operations, despite its somewhat sprawling business structure.
- 2026 Financial Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, reflecting confidence in future growth.
See More
Bausch Health Beats Q1 Estimates with Strong Revenue Growth
- Significant Revenue Growth: Bausch Health reported Q1 revenue of $2.52 billion, a 12% year-over-year increase that surpassed analyst expectations of $2.42 billion, driven primarily by a strong performance in its Bausch + Lomb eyecare segment, which contributed a 9% gain.
- Substantial Net Income Increase: The company's non-GAAP net income surged by 35% to $296 million, translating to $0.78 per share, reflecting successful cost control and operational efficiency, which bolsters investor confidence in the company's financial health.
- Sustained Growth Strategy: Bausch Health has achieved 12 consecutive quarters of year-over-year revenue growth, indicating stability and execution capability despite its sprawling business structure, which may continue to attract investor interest moving forward.
- Stable Outlook: The company maintained its full-year 2026 revenue guidance of $10.67 billion to $10.92 billion, with adjusted EBITDA expected to be between $3.89 billion and $4.01 billion, demonstrating management's confidence in future performance, although no profitability guidance was provided.
See More
